Tradestie Institutional Equity Comparison Engine

SAIQ vs APUS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

APUS Overall Edge

APUS Captures Institutional Edge (1โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apimeds Pharmaceuticals US, Inc. (APUS) driven by superior Growth & Margin while SAIQ counters with relative strength in Momentum & Technical. Fundamentally, SAIQ trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus APUS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SAIQ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against APUS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SAIQ N/M vs APUS N/M Fwd P/E
Growth & Margin Winner APUS
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner SAIQ
1Y +91.9% vs +6.5% ยท 52W Pos 22% vs 15%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
SAIQ US Equity
SAIQ
Institutional Equity
$3.55
+15.26% 1D
Market Cap N/A
1M Return +12.34%
1Y Return +91.89%
Forward P/E N/M
Unified AI Score
50.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
APUS NYSE American
Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations
$2.04
-8.52% 1D
Market Cap $3.4M
1M Return -49.5%
1Y Return +6.47%
Forward P/E N/M
Unified AI Score
48.5 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SAIQ +91.89% APUS +6.47% Spread: +128.54 pp (SAIQ Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SAIQ TTM Op. Margin: N/A APUS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SAIQ vs APUS. Trailing 12-month operating profitability (SAIQ N/A vs APUS 0.0%) and valuation multiples (SAIQ N/M vs APUS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SAIQ (2) vs APUS (6)
Institutional Metric SAIQ APUS Criterion Row Winner
Market Capitalization Scale N/A $3.4M Larger Scale APUS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth APUS
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin APUS
Net Profit Margin Profitability N/A 0.0% Higher Margin APUS
Return on Equity (ROE) Capital Efficiency N/A 0.0% Higher ROE APUS
52-Week Range Position Momentum 22% ($2โ€“$10) 15% ($1โ€“$10) Stronger Trend SAIQ
Beta / 30D Volatility Risk Regime 5.46ฮฒ ยท 390% Vol 2.98ฮฒ ยท 68% Vol Lower Realized Risk APUS
Unified Institutional Score Composite Signal 50.0 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite SAIQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SAIQ vs APUS Buy Guide
SAIQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SAIQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
APUS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live APUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SAIQ nor APUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.